193 related articles for article (PubMed ID: 38686795)
1. Germline
Zhang T; Ambrodji A; Huang H; Bouchonville KJ; Etheridge AS; Schmidt RE; Bembenek BM; Temesgen ZB; Wang Z; Innocenti F; Stroka D; Diasio RB; Largiadèr CR; Offer SM
Elife; 2024 Apr; 13():. PubMed ID: 38686795
[TBL] [Abstract][Full Text] [Related]
2. Germline
Zhang T; Ambrodji A; Huang H; Bouchonville KJ; Etheridge AS; Schmidt RE; Bembenek BM; Temesgen ZB; Wang Z; Innocenti F; Stroka D; Diasio RB; Largiadèr CR; Offer SM
bioRxiv; 2024 Mar; ():. PubMed ID: 37961517
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
Noguchi T; Tanimoto K; Shimokuni T; Ukon K; Tsujimoto H; Fukushima M; Noguchi T; Kawahara K; Hiyama K; Nishiyama M
Clin Cancer Res; 2004 Oct; 10(20):7100-7. PubMed ID: 15501990
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients.
He YF; Wei W; Zhang X; Li YH; Li S; Wang FH; Lin XB; Li ZM; Zhang DS; Huang HQ; Hu B; Jiang WQ
J Clin Pharm Ther; 2008 Jun; 33(3):307-14. PubMed ID: 18452418
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
6. Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals.
Hishinuma E; Narita Y; Saito S; Maekawa M; Akai F; Nakanishi Y; Yasuda J; Nagasaki M; Yamamoto M; Yamaguchi H; Mano N; Hirasawa N; Hiratsuka M
Drug Metab Dispos; 2018 Aug; 46(8):1083-1090. PubMed ID: 29769267
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.
Offer SM; Wegner NJ; Fossum C; Wang K; Diasio RB
Cancer Res; 2013 Mar; 73(6):1958-68. PubMed ID: 23328581
[TBL] [Abstract][Full Text] [Related]
9. Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.
Shrestha S; Zhang C; Jerde CR; Nie Q; Li H; Offer SM; Diasio RB
Clin Pharmacol Ther; 2018 Oct; 104(4):709-718. PubMed ID: 29327356
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Amstutz U; Farese S; Aebi S; Largiadèr CR
J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
[TBL] [Abstract][Full Text] [Related]
11. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
[TBL] [Abstract][Full Text] [Related]
12. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
13. Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter.
Wu R; Nie Q; Tapper EE; Jerde CR; Dunlap GS; Shrestha S; Elraiyah TA; Offer SM; Diasio RB
Cancer Res; 2016 Nov; 76(21):6362-6373. PubMed ID: 27578004
[TBL] [Abstract][Full Text] [Related]
14. Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic
Majounie E; Wee K; Williamson LM; Jones MR; Pleasance E; Lim HJ; Ho C; Renouf DJ; Yip S; Jones SJM; Marra MA; Laskin J
Cold Spring Harb Mol Case Stud; 2020 Feb; 6(1):. PubMed ID: 31871216
[TBL] [Abstract][Full Text] [Related]
15. Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
De Luca O; Salerno G; De Bernardini D; Torre MS; Simmaco M; Lionetto L; Gentile G; Borro M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430399
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA LINC00261 induces chemosensitization to 5-fluorouracil by mediating methylation-dependent repression of DPYD in human esophageal cancer.
Lin K; Jiang H; Zhuang SS; Qin YS; Qiu GD; She YQ; Zheng JT; Chen C; Fang L; Zhang SY
FASEB J; 2019 Feb; 33(2):1972-1988. PubMed ID: 30226808
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD.
Chai J; Dong W; Xie C; Wang L; Han DL; Wang S; Guo HL; Zhang ZL
IUBMB Life; 2015 Mar; 67(3):191-201. PubMed ID: 25873402
[TBL] [Abstract][Full Text] [Related]
18. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
[TBL] [Abstract][Full Text] [Related]
19. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.
Amstutz U; Froehlich TK; Largiadèr CR
Pharmacogenomics; 2011 Sep; 12(9):1321-36. PubMed ID: 21919607
[TBL] [Abstract][Full Text] [Related]
20. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
Mattison LK; Soong R; Diasio RB
Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
